BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 36369502)

  • 21. LLY17, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer.
    Pan L; Chen X; Fu S; Yu W; Li C; Wang T; Lo HW; Lin J
    Breast Cancer Res Treat; 2020 May; 181(1):31-41. PubMed ID: 32240456
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Arctigenin inhibits STAT3 and exhibits anticancer potential in human triple-negative breast cancer therapy.
    Feng T; Cao W; Shen W; Zhang L; Gu X; Guo Y; Tsai HI; Liu X; Li J; Zhang J; Li S; Wu F; Liu Y
    Oncotarget; 2017 Jan; 8(1):329-344. PubMed ID: 27861147
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bt354 as a new STAT3 signaling pathway inhibitor against triple negative breast cancer.
    Chen Y; Ji M; Zhang S; Xue N; Xu H; Lin S; Chen X
    J Drug Target; 2018 Dec; 26(10):920-930. PubMed ID: 29595328
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer.
    Tian J; Chen X; Fu S; Zhang R; Pan L; Cao Y; Wu X; Xiao H; Lin HJ; Lo HW; Zhang Y; Lin J
    Breast Cancer Res Treat; 2019 Jun; 175(3):553-566. PubMed ID: 30852762
    [TBL] [Abstract][Full Text] [Related]  

  • 25. RNA-binding protein NONO contributes to cancer cell growth and confers drug resistance as a theranostic target in TNBC.
    Kim SJ; Ju JS; Kang MH; Eun JW; Kim YH; Raninga PV; Khanna KK; Győrffy B; Pack CG; Han HD; Lee HJ; Gong G; Shin Y; Mills GB; Eyun SI; Park YY
    Theranostics; 2020; 10(18):7974-7992. PubMed ID: 32724453
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stat3/Oct-4/c-Myc signal circuit for regulating stemness-mediated doxorubicin resistance of triple-negative breast cancer cells and inhibitory effects of WP1066.
    Cheng CC; Shi LH; Wang XJ; Wang SX; Wan XQ; Liu SR; Wang YF; Lu Z; Wang LH; Ding Y
    Int J Oncol; 2018 Jul; 53(1):339-348. PubMed ID: 29750424
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ilamycin C induces apoptosis and inhibits migration and invasion in triple-negative breast cancer by suppressing IL-6/STAT3 pathway.
    Xie Q; Yang Z; Huang X; Zhang Z; Li J; Ju J; Zhang H; Ma J
    J Hematol Oncol; 2019 Jun; 12(1):60. PubMed ID: 31186039
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Loss of Wwox drives metastasis in triple-negative breast cancer by JAK2/STAT3 axis.
    Chang R; Song L; Xu Y; Wu Y; Dai C; Wang X; Sun X; Hou Y; Li W; Zhan X; Zhan L
    Nat Commun; 2018 Aug; 9(1):3486. PubMed ID: 30154439
    [TBL] [Abstract][Full Text] [Related]  

  • 29. GGNBP2 suppresses triple-negative breast cancer aggressiveness through inhibition of IL-6/STAT3 signaling activation.
    Liu J; Liu L; Yagüe E; Yang Q; Pan T; Zhao H; Hu Y; Zhang J
    Breast Cancer Res Treat; 2019 Feb; 174(1):65-78. PubMed ID: 30450530
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Salidroside inhibits migration, invasion and angiogenesis of MDA‑MB 231 TNBC cells by regulating EGFR/Jak2/STAT3 signaling via MMP2.
    Kang DY; Sp N; Kim DH; Joung YH; Lee HG; Park YM; Yang YM
    Int J Oncol; 2018 Aug; 53(2):877-885. PubMed ID: 29901185
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel potent azetidine-based compounds irreversibly inhibit Stat3 activation and induce antitumor response against human breast tumor growth in vivo.
    Yue P; Zhu Y; Brotherton-Pleiss C; Fu W; Verma N; Chen J; Nakamura K; Chen W; Chen Y; Alonso-Valenteen F; Mikhael S; Medina-Kauwe L; Kershaw KM; Celeridad M; Pan S; Limpert AS; Sheffler DJ; Cosford NDP; Shiao SL; Tius MA; Lopez-Tapia F; Turkson J
    Cancer Lett; 2022 May; 534():215613. PubMed ID: 35276290
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined inhibition of JAK2-STAT3 and SMO-GLI1/tGLI1 pathways suppresses breast cancer stem cells, tumor growth, and metastasis.
    Doheny D; Sirkisoon S; Carpenter RL; Aguayo NR; Regua AT; Anguelov M; Manore SG; Arrigo A; Jalboush SA; Wong GL; Yu Y; Wagner CJ; Chan M; Ruiz J; Thomas A; Strowd R; Lin J; Lo HW
    Oncogene; 2020 Oct; 39(42):6589-6605. PubMed ID: 32929154
    [TBL] [Abstract][Full Text] [Related]  

  • 33. STAT3-induced HLA-F-AS1 promotes cell proliferation and stemness characteristics in triple negative breast cancer cells by upregulating TRABD.
    Wu D; Jia H; Zhang Z; Li S
    Bioorg Chem; 2021 Apr; 109():104722. PubMed ID: 33618253
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Picrasidine G decreases viability of MDA-MB 468 EGFR-overexpressing triple-negative breast cancer cells through inhibition of EGFR/STAT3 signaling pathway.
    Yamashita N; Kondo M; Zhao S; Li W; Koike K; Nemoto K; Kanno Y
    Bioorg Med Chem Lett; 2017 Jun; 27(11):2608-2612. PubMed ID: 28427809
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A new synthetic derivative of cryptotanshinone KYZ3 as STAT3 inhibitor for triple-negative breast cancer therapy.
    Zhang W; Yu W; Cai G; Zhu J; Zhang C; Li S; Guo J; Yin G; Chen C; Kong L
    Cell Death Dis; 2018 Oct; 9(11):1098. PubMed ID: 30368518
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Growth-suppressive activity of raloxifene on liver cancer cells by targeting IL-6/GP130 signaling.
    Wang Y; Ma H; Zhao C; Liu T; Yan D; Jou D; Li H; Zhang C; Lü J; Li C; Lin J; Li S; Lin L
    Oncotarget; 2017 May; 8(20):33683-33693. PubMed ID: 28430601
    [TBL] [Abstract][Full Text] [Related]  

  • 37. VGLL4 interacts with STAT3 to function as a tumor suppressor in triple-negative breast cancer.
    Song H; Luo Q; Deng X; Ji C; Li D; Munankarmy A; Jian W; Zhao J; Fang L
    Exp Mol Med; 2019 Nov; 51(11):1-13. PubMed ID: 31748508
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rational drug design of benzothiazole-based derivatives as potent signal transducer and activator of transcription 3 (STAT3) signaling pathway inhibitors.
    Gao D; Jin N; Fu Y; Zhu Y; Wang Y; Wang T; Chen Y; Zhang M; Xiao Q; Huang M; Li Y
    Eur J Med Chem; 2021 Apr; 216():113333. PubMed ID: 33689932
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nitric Oxide-Releasing Drug Glyceryl Trinitrate Targets JAK2/STAT3 Signaling, Migration and Invasion of Triple-Negative Breast Cancer Cells.
    Bouaouiche S; Ghione S; Sghaier R; Burgy O; Racoeur C; Derangère V; Bettaieb A; Plenchette S
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445170
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Luteolin suppresses androgen receptor-positive triple-negative breast cancer cell proliferation and metastasis by epigenetic regulation of MMP9 expression via the AKT/mTOR signaling pathway.
    Wu HT; Lin J; Liu YE; Chen HF; Hsu KW; Lin SH; Peng KY; Lin KJ; Hsieh CC; Chen DR
    Phytomedicine; 2021 Jan; 81():153437. PubMed ID: 33352494
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.